X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

IRA Impacts: Cancer treatment research and development

By Andrew Powaleny  |    March 23, 2023
Last month marked the one-year anniversary of the reignited Cancer Moonshot, the White House’s ambitious goal of reducing the death rate from cancer by at least 50% over the next 25 years. Much of...   Read More

State policymakers can protect American innovation and help Americans live longer, healthier lives

By Mark Reisenauer and Stephen J. Ubl  |    February 9, 2023
For the second year in a row, life expectancy is on the decline in America. The leading causes of death across the United States include cancer and chronic diseases. Even when patients are able to...   Read More

ICYMI: Cancer death rate continues to decline due to treatment advances

By Matthew Norawong  |    January 25, 2023
Earlier this month, the American Cancer Society (ACS) released its annual report, Cancer Statistics 2023, finding the overall cancer mortality rate has declined 33% since peaking in 1991, leading to...   Read More

Novel medicines approved in 2022 offer increased treatment options for patients

By Andrew Powaleny  |    January 23, 2023
2022 marked another year of significant progress by biopharmaceutical research companies conducting lifesaving research and development for innovative medicines with a total of 45 new medicine...   Read More

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

By Matthew Norawong  |    December 1, 2022
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...   Read More

ICYMI: PhRMA COO Lori Reilly Esq. speaks with Jacob Van Naarden about the future of cancer research

By Emilie Signora  |    November 8, 2022
Our health care ecosystem has made tremendous progress in the fight against cancer, with the cancer death rate falling 32% from its peak in 1991. On November 3, PhRMA sponsored The Atlantic’s People...   Read More

Protecting treatment advances for breast cancer

By Jocelyn Ulrich  |    October 31, 2022
Since the 1980s, October has been recognized as National Breast Cancer Awareness Month — an opportunity for us to unite as a community to honor those who have had breast cancer and raise awareness...   Read More

Key takeaways from ASCO's annual meeting

By Michael Ybarra  |    June 10, 2022
Last weekend, health care professionals, patients, scientists and biopharmaceutical researchers gathered for the American Society of Clinical Oncology's (ASCO) annual meeting. With over 200 sessions...   Read More

ICYMI: First pediatric patient to receive CAR-T cell therapy celebrates 10 years of being cancer-free

By Matthew Norawong  |    May 25, 2022
Recently, NBC News’ Today did a profile on one of the first pediatric patients in the world to receive a CAR-T cell therapy for the treatment of acute lymphoblastic leukemia (ALL). In April 2012, the...   Read More

Report: More than 500 medicines in development to treat disorders of the blood

By Andrew Powaleny  |    May 18, 2022
Today, PhRMA released a new report covering 549 medicines in development to potentially treat disorders of the blood, including blood cancers. These conditions pose a significant and ongoing unmet...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates